Esperion reveals robust Q1 growth, FDA approval boosts By Investing.com
Esperion Therapeutics Inc. (NASDAQ:) has reported a significant surge in its first-quarter revenue for 2024, with a total revenue of ...
Esperion Therapeutics Inc. (NASDAQ:) has reported a significant surge in its first-quarter revenue for 2024, with a total revenue of ...
(Reuters) - About one in five samples of commercial milk in the U.S. tested positive for traces of bird flu ...
(Reuters) - The U.S. Food and Drug Administration on Thursday said it had issued warning letters and filed civil money ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of ...
FOSTER CITY, Calif. - Gilead Sciences Inc . (NASDAQ: NASDAQ:) announced the U.S. Food and Drug Administration (FDA) has approved ...
The United States Supreme Court heard oral arguments Tuesday in a case that could further impact a woman’s right to ...
© Reuters. Humacyte, Inc. (HUMA), a biotechnology company specializing in regenerative medical technologies, has reported its financial results for the ...
© Reuters. FLORHAM PARK, N.J. - Celularity Inc. (NASDAQ: CELU), a biotechnology firm specializing in regenerative medicine, has formally requested ...
In this photo illustration, the Madrigal Pharmaceuticals logo is displayed on a smartphone screen. Rafael Henrique | SOPA Images | Lightrocket ...
Positive news for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), after the US Food and Drug Administration (FDA) ...